Results from a meta-analysis.
Risk in diabetes varies by age, BMI, and HbA1c but is similar for T1D and T2D.
Recommendations for bariatric and metabolic surgery during and after the COVID-19 pandemic.
The findings for 2018-2019 were recently published by NHS Digital.
The severity of COVID-19 varies between people.
Results from the UK Biobank.
International expert panel recommendations for managing patients with diabetes and at-risk for severe COVID-19.
Findings using data from the Nurses’ Health Study II.
Weight reduction was associated with BP reduction with both treatments.
Incidence of depression and first‐line antidepressant therapy in people with obesity and depression in primary care in the UK.
No additive effect on glucose, but weight loss improves.
Glycemia, body weight, and BP all improved.
Findings from the Metformin use in Obese-Pregnant women trial.
Results from a nested cohort study using the UK CPRD data.
Results should be interpreted with caution because of variable adherence and other factors.
Previous studies have showed mixed results with fewer CRC cases, younger populations.
Liraglutide 3 mg is the dose approved for weight loss, not glycemic control.
